¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02
±³À°ÀÏÀÚ : 2022-10-02
±³À°Àå¼Ò : ¾Ú¹è¼­´õ ¼­¿ï Ç®¸¸ È£ÅÚ ±×·£µåº¼·ë 2F  
±³À°ÁÖÁ¦ : 2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ  
´ã´çÀÚ : ÃÖ°æ¼ö
¿¬¶ôó : 02-2038-7674  
À̸ÞÀÏ : gschoi@humming.co.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í Á¤È¸¿ø4¸¸¿ø,Æò»ýȸ¿ø2¸¸¿ø,Àü°øÀÇ1¸¸¿ø,ºñȸ¿ø20¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:30~09:40 Antipruritic effect of synthetic TRPM8 channel agonist (cryosim-1) gel on histaminergic and non-histaminergic itch in healthy human skin: a single-blind, randomized vehicle-controlled study  À̼ҿ¬(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:40~09:50 Long-Term Efficacy of Dupilumab in South Korean Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Open-Label Extension Trial  ³ëÀ±Áø(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:50~10:00 Interferon-¥ã inducible protein 10 promotes Th2 inflammation by activating IL-4-secreting Th2 cells, exacerbating mite allergen-sensitized atopic dermatitis  ¹æÁø¼±(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:00~10:10 ASSOCIATION BETWEEN METABOLIC SYNDROME AND ATOPIC DISEASES INCLUDING ATOPIC DERMATITIS, ALLERGIC RHINITIS AND ASTHMA  ±Ç¹ÎÁ¤(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:10~10:35 Interpretations of research data for atopic dermatitis  ÀÌ¿µº¹(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:35~11:00 Practical laboratory tests in your clinic  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:00~11:20 What's new in researches of atopic dermatitis?  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
È޽Ġ10-02 ±×·£µåº¼·ë 11:20~11:40 Break time  () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:40~12:20 Recognizing the multi-dimensional impact of atopic dermatitis patients and systemic comorbidities  Jonathan Silverberg(George Washington University School of Medicine and Health Sciences, USA) 
½Ä»ç 10-02 ±×·£µåº¼·ë 12:20~13:10   () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:10~13:20 Mycosis fungoides Found in Patients with Atopic Dermatitis Refractory to Dupilumab  ±¹Çüµ·(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:20~13:30 New On of Alcohol Flushing in Patients with Atopic Dermatitis Treated with Dupilumab: Is It an Underrecognized Adverse Event?  ½Éµ¿Çö(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:30~13:40 Preventive effects of topical diquafosol on dupilumab-associated conjunctivitis in atopic dermatitis: an open-label prospective study  ÀÌÁø¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:40~13:50 Effects of Gamma-Linolenic Acid Adjuvant Therapy in Patients with Atopic Dermatitis: A Survey Study  µµÁöÀ±(Ä«Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:50~14:30 Optimal use of Janus kinase inhibitors and dupilumab for atopic dermatitis based on the current evidence  Masahiro Kamata(Teikyo University, Japan) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:30~14:55 Update in pediatric atopic dermatitis  Àå¿ëÇö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:55~15:20 Treatments of pediatric atopic dermatitis : Face to unmet needs  °íÇöâ(ºÎ»êÀÇ´ë) 
È޽Ġ10-02 ±×·£µåº¼·ë 15:20~15:40 Break time  () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 15:40~16:20 Treat to target in atopic dermatitis : Significance and strategy  Yoko Kataoka(Osaka Habikino Medical Center, Japan) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:20~16:45 Biologics & small molecules treatment of atopic dermatitis patients : How and when?  ½Å¹Î°æ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:45~17:10 Upcoming therapies of atopic dermatitis compared with psoriasis : What's in the pipeline?  ¹èÀ¯ÀÎ(ÇѸ²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ÀÏÂ÷ÀÇ·á±â°ü °¨¿°º´ ´ëÀÀ ¿Â¶óÀÎ ¿¬¼ö±³À°(Á¦4Â÷) : 2022-10-04
´ÙÀ½±Û ´ëÇÑÅëÁõÇÐȸ ºÎ¿ï°æÁöȸ Áý´ãȸ : 2022-10-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 56 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 39 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 39 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 51 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 40 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 37 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 13 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 14 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 33 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 17 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 15 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 37 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 27 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 31 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 24 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷